{"id":"NCT01743001","sponsor":"Actelion","briefTitle":"Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome","officialTitle":"A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-05-21","primaryCompletion":"2016-12-01","completion":"2016-12-01","firstPosted":"2012-12-06","resultsPosted":"2018-01-30","lastUpdate":"2018-02-23"},"enrollment":226,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Arterial Hypertension"],"interventions":[{"type":"DRUG","name":"Macitentan 10 mg","otherNames":["ACT-064992"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Macitentan","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Clinical study to assess the efficacy, safety, and tolerability of macitentan in subjects with Eisenmenger Syndrome.","primaryOutcome":{"measure":"Change From Baseline to Week 16 in Exercise Capacity, as Measured by 6-minute Walk Distance (6MWD)","timeFrame":"From baseline to Week 16","effectByArm":[{"arm":"Macitentan","deltaMin":368.7,"sd":74.5},{"arm":"Placebo","deltaMin":380.3,"sd":76.3}],"pValues":[{"comp":"OG000 vs OG001","p":"0.6120"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":21},"locations":{"siteCount":55,"countries":["United States","Austria","Bulgaria","Chile","China","France","Germany","Greece","Israel","Malaysia","Mexico","Philippines","Poland","Portugal","Romania","Russia","Serbia","Spain","Turkey (TÃ¼rkiye)","United Kingdom","Vietnam"]},"refs":{"pmids":["30586694"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":114},"commonTop":["Headache","Upper respiratory tract infection","Nasopharyngitis","Bronchitis","Haemoptysis"]}}